Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Insight Brief
Wayne R. Hogrefe, Ph.D | March 19, 2018

A Proactive Approach to Ebola Vaccine Development

Best practices for rapid test development and regulatory approvals
Over the last three years, Ebola vaccine research has transitioned from lightly funded research in the public health arena to both biotech companies and large pharma. New approaches to vaccine design have been brought to the mainstream allowing them to address other emerging and established infectious diseases.

In this insight brief, you will learn best practices for rapid test development and regulatory approvals and explore how laboratory CROs are moving from a reactive to proactive approach to Ebola Vaccine test development.

Related Services:
Assays to drive success in anti-infective and vaccine development

Extensive expertise for vaccine assay development and diagnostics

Delivery Excellence for Anti-infective and Vaccine Development

Supply chain and quality management systems to ensure sample integrity for high-quality data delivery

Q2 Solutions Anti-infective and Vaccine Development Services

Zika Vaccine Research: Complex Steps Toward a Critical Need

Overcoming Zika vaccine development challenges

Read More